Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (including related party amounts of $72 and $228, respectively) | $14,379 | $15,377 |
| General and administrative (including related party amounts of $85 and $134, respectively) | 5,327 | 5,041 |
| Total operating expenses | 19,706 | 20,418 |
| Loss from operations | (19,706) | (20,418) |
| Interest income | 2,070 | 2,703 |
| Net loss | $(17,636) | $(17,715) |
| Net loss per share, basic and diluted | $(0.29) | $(0.31) |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s G&A?
- Design Therapeutics, Inc. (DSGN) reported G&A of $5.33M in Q1 2026.
- How has Design Therapeutics, Inc.'s G&A changed year-over-year?
- Design Therapeutics, Inc.'s G&A increased by 5.7% year-over-year, from $5.04M to $5.33M.
- What is the long-term trend for Design Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s G&A has grown at a 16.5% compound annual growth rate (CAGR), from $11.05M to $20.34M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Design Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude